+7%

est. 2Y upside i

Series A

Nudge is building the best technology for interfacing with the brain to improve people's lives — safely, precisely, and without surgery. Their first platform is based on non-invasive focused ultrasound, which allows them to stimulate and image the brain with millimeter precision.

Rank

#1889

Sector

Neurotech

Est. Liquidity

~7Y

Data Quality

Data: Low

Joining Nudge as an early employee carries extreme uncertainty due to missing financial data and pre-revenue status.

Last updated: July 19, 2026

Bull (15%)+180%

If Nudge successfully commercializes its ultrasound brain interface and gains FDA approval within 2 years, rapid revenue growth could follow. Entry valuation unknown, but strong IP moat supports high multiples.

Base (50%)+30%

Moderate progress in clinical trials and partnerships, with gradual revenue ramp. Valuation may reflect standard multiple for early-stage neurotech.

Bear (35%)-100%

Technical or regulatory setbacks, or inability to raise further funding, leading to exit below the $100M preference stack, resulting in zero recovery for common stock.

Est. time to liquidity~7.0 years

Preference Stack Risk

severe

Funding Intensity

10000%

$100M in total funding with no disclosed valuation; preference overhang equals 100% of implied investment, meaning common recovers only above that threshold.

Dilution Risk

high

High capital intensity makes future funding highly likely, diluting common equity significantly.

Secondary Liquidity

none

No secondary market activity reported; early-stage private company with no liquidity options.

Engineering — 9 roles

Research — 5 roles

Talent — 3 roles

All (Unspecified) — 2 roles

Operations — 1 role

View all 20 open roles at Nudge →

Last updated: March 10, 2026

Questions to Ask at the Interview

Strategic questions based on Nudge's data — designed to show you've done your homework.

  • 1

    “How does Nudge's ultrasound technology compare to existing invasive brain interfaces in terms of cost, efficacy, and scalability?”

  • 2

    “What is the expected timeline to first FDA clearance, and what clinical trial milestones de-risk that path?”

  • 3

    “How does the current equity grant interact with the $100M preferred liquidation preference, and what are the dilution assumptions in future rounds?”

Community

Valuation Sentiment

Our model estimates +7% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.